Valeant acquired Tasmar (tolcapone) from Roche and re-launched the product in the US and other countries throughout the rest of the world in the summer of 2004. Tasmar will be rolled out across the EU throughout 2005.
Tasmar is an adjunctive therapeutic agent used in combination with levodopa and carbidopa for patients with severe Parkinson’s disease who are not responding satisfactorily or are not appropriate candidates for other adjunctive therapies. Tasmar is classified as a catechol-O-methyl transferase (COMT) inhibitor.
“Tasmar is an important part of Valeant’s neurology business and we have been looking forward to globally commercializing the product since we acquired it in 2004,” said Valeant’s president and CEO, Timothy Tyson. “We are pleased to bring the product to patients suffering from Parkinson’s disease in the European Union.”